Tear Levels of Insulin-Like Growth Factor Binding Protein 3 Correlate With Subbasal Nerve Plexus Changes in Patients With Type 2 Diabetes Mellitus

Whitney L. Stuard, Rossella Titone, and Danielle M. Robertson

The Department of Ophthalmology, The University of Texas Southwestern Medical Center, Dallas, Texas, United States

PURPOSE. This study investigated the expression of insulin-like growth factor binding protein-3 (IGFBP-3) in basal tears of patients with type 2 diabetes mellitus compared to nondiabetic controls; and correlated tear levels of IGFBP-3 with morphologic changes in the subbasal nerve plexus and density of basal corneal epithelial cells.

METHODS. This was a single visit, cross-sectional study. Diabetic and control subjects were matched for age, sex, smoking status, and body mass index. Tear levels of IGFBP-3 were measured using ELISA. Corneal nerve and basal epithelial cell changes were measured using in vivo confocal microscopy.

RESULTS. Tear levels of IGFBP-3 were 3.5-fold higher in those with diabetes. Patients with diabetes also showed a reduction in nerve fiber layer, nerve branch density, and corneal basal epithelial cell density. There was no significant difference in corneal sensitivity. IGFBP-3 levels were highly correlated with nerve fiber length and branch density; while hemoglobin (Hb)A1c was only moderately correlated. There were no significant differences in the clinical or subjective signs of dry eye between groups, indicating that tear levels of IGFBP-3 and corneal nerve changes were not due to the presence of mild dry eye.

CONCLUSIONS. These findings indicate that tear levels of IGFBP-3 are more tightly correlated to nerve fiber changes in diabetes than HbA1c. Future studies that stratify the severity of diabetic disease with tear levels of IGFBP-3 are needed to validate this finding.

Keywords: cornea, epithelium, IGFBP-3, subbasal nerve plexus, T2DM
corneal sensitivity and the morphology of the subbasal nerve plexus using remote controlled scanning in vivo confocal microscopy.

**MATERIALS AND METHODS**

**Study Design and Population**

This was a single visit, cross-sectional, masked study designed to investigate tear levels of IGFBP-3 in relation to corneal nerve fiber morphology. This study adhered to the tenets of the Declaration of Helsinki. All study procedures were approved by the institutional review board at the University of Texas Southwestern Medical Center. All patients signed written informed consent before participating in this study. Patients were recruited through the Ophthalmology Clinic at the Aston Ambulatory Care Center at the University of Texas Southwestern Medical Center, Dallas, Texas, United States. Patients were placed into one of two groups according to their medical history: those with type 2 diabetes mellitus and nondiabetic controls. For inclusion in the diabetes group, a physician diagnosis was required. Normal controls consisted of healthy adults aged 18 years and older that were noncontact lens wearers or had no history of recent contact lens wear within the last year. For women who were not menopausal and had a negative medical history for tubal ligation or hysterectomy, a urine pregnancy test was performed to rule out possible pregnancy. Exclusion criteria for both diabetic and control groups included patients with a recent history of ocular surgery, trauma, use of topical glaucoma medications or other topical ophthalmic medications, contact lens wear, pregnancy or lactation, type 1 diabetes mellitus, respiratory disorders such as asthma or chronic obstructive pulmonary disease, end-stage renal disease, alcoholism, infectious disease, cancer, or any uncontrolled systemic disease that may adversely affect study results. For all outcome measures, the clinical investigator (DMR) was masked to the health status of the patient. Groups were matched for age, sex, obesity, and smoking status. Outcome measures included anthropometric measurements for the calculation of body mass index (BMI), and waist-to-height ratio. Each patient then underwent the following: serology testing, blood pressure measurement; a basic eye examination that included dry eye testing (described below); and a dilated fundus examination to check for the presence of diabetic retinopathy, tear collection, and the morphology of the subbasal nerve plexus and the basal epithelium. The right eye of each patient was used. As the last clinical test, basal tear production was obtained by a trained investigator (DMR).

**Assessment of the Cornea and Tear Film**

The cornea and ocular surface were assessed by a single clinical examiner (DMR). A brief biomicroscopic examination of the lids, lashes, conjunctiva, and cornea was performed to rule out any existing corneal pathology. The cornea and ocular surface were evaluated for staining using fluorescein, and measures of tear film break-up time (TFBUT) and basal tear production were obtained. For the determination of TFBUT, 2 μL of 2.0% nonpreserved fluorescein (Greenpark Pharmacy, Houston, TX, USA) were instilled onto the superior bulbar conjunctiva. After three normal blinks, the time between the last blink and the first dark spot was timed using a stopwatch. Three readings were recorded with 30-second rest periods in between. For patients with a stable tear film that did not show signs of breakup, timing was truncated at 30 seconds. Immediately following the measurement of tear film breakup time, the cornea was evaluated for fluorescein staining. Staining was graded according to the National Eye Institute scale for corneal staining in five regions using a scale of 0 to 3. For all fluorescein-based measurements, a Watten #12 filter was used. As the last clinical test, basal tear production was assessed using a Schirmer’s tear test without anesthesia. The Schirmer’s strip was placed in the lower fornix near the lateral canthus and the subject was instructed to close their eyes. The length of the wetted area after 5 minutes was measured. All tests were performed for both eyes and the values for the right and left eyes were averaged to achieve a final measurement.

**Tear Collection**

Tear collection was performed as the first clinical test. Tears were collected from the temporal inferior tear meniscus on both eyes of each subject using 1 or 2 μL glass capillary tubes (Drummond, Fischer Scientific, Houston, TX, USA). The inferior tear meniscus was visualized using a slit lamp biomicroscope (Haag-Streit, Köniz, Switzerland) with low illumination. We collected 5 μL of minimally stimulated basal tear fluid from each eye. Care was taken to avoid touching the eye to minimize reflex tearing. Tears from each eye were pooled to reach a final volume of 10 μL. Samples were immediately placed on ice and then stored at −80°C until use. To control for diurnal fluctuations, all samples were collected between 8 AM and noon by a single trained investigator (DMR).

**Conical Sensitivity**

After evaluation of the cornea and ocular surface, corneal sensitivity was measured in the right eye using anesthesiometer (Cochet-Bonnet esthesiometer; Luneau, Paris, France). The esthesiometer contained a 0.08-mm diameter nylon filament. The filament was used to appitalize the inferior cornea approximately 2 mm above the inferior limbus. Initial measurements were performed with the filament fully extended to 6.0 mm. The filament length was systematically reduced in increments of 0.5 mm until the patient reported >2 of the 4 stimuli at one increment. False presentations were included to control for bias in patient response. All measurements were obtained by a trained investigator (DMR).

**In Vivo Confocal Microscopy**

In vivo confocal microscopy was performed using a modified HRT-RCM confocal microscope (Heidelberg Engineering, Heidelberg, Germany) to collect images of the corneal subbasal nerve plexus and the basal epithelium. The right eye of each patient was scanned. Prior to scanning, one drop of topical proparacaine (Alcon Laboratories, Ft. Worth, TX, USA) was instilled into both eyes. Eye gel (GenTeal; Alcon Laboratories) was applied to the confocal cap to optically couple the confocal tip to the cornea. Repeat scans were performed across the midperipheral and central cornea, moving from the superior temporal region toward the inferior nasal area. Scans were performed in real time while live streaming high-resolution images to an external hard drive. A remote control was used to adjust the focus of the objective and to continuously move the plane of focus back and forth through the cornea. Images of the subbasal nerve plexus were reconstructed in the laboratory to generate a minimum of eight nonoverlapping regions. Sequential image frames were stacked using microscopy automation and image analysis software (MetaMorph; Molecular Devices, Sunnyvale, CA, USA) and Fiji (provided in the public domain by the National Institutes of Health [NIH], Bethesda, MD, USA) to generate a maximum intensity projection to account for all nerves regardless of focal plane. This allowed for the generation of a single composite image (400 × 400 μm). Confocal images were...
then analyzed for determination of nerve fiber length, which is defined as the total length in μm of all the nerves in the 400 × 400 μm confocal microscopy image; and nerve branch density, defined as the total number of branch points per μm² in the 400 × 400 μm confocal microscopy image. Corneal epithelial basal cell density, which is the total number of epithelial cells in the 400 × 400 μm confocal image, was also calculated. Quantification of nerve fiber length was measured by manually tracing the nerves within each image using image analysis software (Molecular Devices). Epithelial cell density was determined by manually counting the epithelial cells using the FIJI cell counter plugin.

### Anthropometric Measurements

Neck, waist, and hip circumferences were measured using a standard seamstress tape measure. Waist circumference was measured at the midpoint between the lower palpable rib and the top of the iliac crest. Hip circumference was measured at the widest area of the buttocks. To rule-out effects of obesity between study groups, body mass index, which was calculated based upon current height and weight, measured at the time of examination. Body mass index was classified as: underweight (≤18.5); normal (18.6–24.9); overweight (25.0–29.9); and obese (≥30.0).

### Systemic Biomarkers

Phlebotomy was performed in nonfasted patients for assessment of systemic inflammatory and metabolic biomarkers. This included measurement of glycosylated hemoglobin (HbA1c), high-sensitivity C-reactive protein (hsCRP), and a lipid panel. Serology testing was performed at Quest Laboratories (Dallas, TX, USA). Systolic and diastolic blood pressure measurements were also obtained using an automated wrist sphygmomanometer.

### ELISA

Human tear samples were assessed for the presence of insulin like growth factor binding protein 3 (IGFBP-3). A commercial kit (IGFBP-3 Quantikine ELISA kit; R&D Systems, Minneapolis, MN, USA) was used to determine tear concentration. We took 10 μL of pooled tear samples from both eyes of each patient and diluted 1:10 using calibrator diluent. The assay was performed according to manufacturer instructions. The samples were then read at an absorbance of 450 nm and compared against a standard curve of known concentrations. Concentrations of IGFBP-3 in tear samples were calculated and corrected by the dilution factor. Patients with IGFBP-3 levels outside the linear range of the standard were excluded.

### Statistics

Statistical analysis was performed using commercial software (SigmaPlot 12.5; Systat Software, Inc., San Jose, CA, USA). A Shapiro-Wilk test was used to test whether the data was normally distributed. For data with a normal distribution, data are represented as mean ± standard deviation and the 95% confidence interval is presented. For analysis between two groups with a normal distribution, a Student’s t-test was performed. For data with a nonnormal distribution, data are presented as the median with a range (min–max). Analysis between two groups with a nonnormal distribution used a Mann-Whitney rank sum test. For analysis between nominal variables, a χ² test was used. Linear regression analysis was performed to test for relationships between tear levels of IGFBP-3 and nerve fiber length, nerve branch density; and HbA1c. Statistical significance was set at P < 0.05.

### RESULTS

A total of 40 participants were recruited for this study. Participant demographics are displayed in Table 1. There were no differences in patient age between groups (58.8 ± 10.2 years of age versus 53.5 ± 9.7 years of age, \( P = 0.065 \), t-test). In the diabetic group, 33.5% of the participants were male and 66.7% were female. In the control group, 45.0% of participants were male and 55.0% were female. This was not significantly different \( (P = 0.111, \chi² \text{test}) \). Test and control groups were also matched for smoking status \( (11.2\% \text{ compared to } 14.0\%, P = 0.669, \chi² \text{test}) \) and body mass index confirmed that all subjects were obese \((33.5 \pm 6.5 \text{ and } 31.2 \pm 4.3, \text{ respectively, } P = 0.222, \chi² \text{test}) \). Serologic and anthropometric data are shown in Table 2. Table 2. There were no significant differences in neck, waist, or hip circumferences between groups \( (P = 0.317, P = 0.055, \text{ and } P = 0.375, \text{ respectively}) \).

### TABLE 1. Patient Demographics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Type 2 DM</th>
<th>Control</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>58.8 ± 10.2</td>
<td>53.5 ± 9.7</td>
<td>0.065</td>
</tr>
<tr>
<td>Range</td>
<td>32–75</td>
<td>34–75</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>6 (33.3)</td>
<td>10 (45.0)</td>
<td>0.111</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>12 (66.7)</td>
<td>12 (55.0)</td>
<td></td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoker, n (%)</td>
<td>2 (11.2)</td>
<td>3 (14.0)</td>
<td>0.669</td>
</tr>
<tr>
<td>Nonsmoker, n (%)</td>
<td>16 (88.8)</td>
<td>19 (86.0)</td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>33.5 ± 6.3</td>
<td>31.3 ± 4.5</td>
<td>0.222</td>
</tr>
<tr>
<td>95% CI</td>
<td>30.3, 36.7</td>
<td>29.4, 33.2</td>
<td></td>
</tr>
</tbody>
</table>

### TABLE 2. Serologic and Anthropometric Data

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Type 2 DM</th>
<th>Control</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neck circumference†, in.</td>
<td>15.7 ± 1.2</td>
<td>15.3 ± 1.5</td>
<td>0.317</td>
</tr>
<tr>
<td>95% CI</td>
<td>15.1, 16.3</td>
<td>14.7, 15.9</td>
<td></td>
</tr>
<tr>
<td>Waist circumference†, in.</td>
<td>43.0 ± 6.7</td>
<td>39.4 ± 4.7</td>
<td>0.555</td>
</tr>
<tr>
<td>95% CI</td>
<td>39.7, 46.3</td>
<td>37.4, 41.4</td>
<td></td>
</tr>
<tr>
<td>Hip circumference†, in.</td>
<td>45.1 ± 4.9</td>
<td>45.9 ± 4.1</td>
<td>0.375</td>
</tr>
<tr>
<td>95% CI</td>
<td>42.7, 47.5</td>
<td>42.2, 45.6</td>
<td></td>
</tr>
<tr>
<td>Waist-to-height ration†</td>
<td>0.6 ± 0.1</td>
<td>0.6 ± 0.1</td>
<td>0.078</td>
</tr>
<tr>
<td>95% CI</td>
<td>0.66, 0.74</td>
<td>0.66, 0.74</td>
<td></td>
</tr>
<tr>
<td>HbA1c*, %</td>
<td>7.5</td>
<td>5.8</td>
<td>&lt;0.001†</td>
</tr>
<tr>
<td>(range)</td>
<td>(5.9–9.9)</td>
<td>(4.8–6.3)</td>
<td></td>
</tr>
<tr>
<td>hsCRP*, mg/L</td>
<td>3.6</td>
<td>2.0</td>
<td>0.808</td>
</tr>
<tr>
<td>(range)</td>
<td>(0.4–63.9)</td>
<td>(0.2–18.1)</td>
<td></td>
</tr>
<tr>
<td>Cholesterol†, mg/dL</td>
<td>177.8 ± 51.5</td>
<td>200.3 ± 54.4</td>
<td>0.126</td>
</tr>
<tr>
<td>95% CI</td>
<td>152.5, 203.3</td>
<td>185.8, 214.8</td>
<td></td>
</tr>
<tr>
<td>HDL* mg/dL</td>
<td>44.0</td>
<td>55.0</td>
<td>0.040‡</td>
</tr>
<tr>
<td>(range)</td>
<td>(30–81)</td>
<td>(32–119)</td>
<td></td>
</tr>
<tr>
<td>Triglyceride*, mg/dL</td>
<td>169.0</td>
<td>86.0</td>
<td>0.004‡</td>
</tr>
<tr>
<td>(range)</td>
<td>(73–366)</td>
<td>(65–252)</td>
<td></td>
</tr>
<tr>
<td>Systolic BP*, mm Hg</td>
<td>151.0</td>
<td>133.0</td>
<td>0.206</td>
</tr>
<tr>
<td>(range)</td>
<td>(115–220)</td>
<td>(61–125)</td>
<td></td>
</tr>
<tr>
<td>Diastolic BP†, mm Hg</td>
<td>90.1 ± 18.7</td>
<td>89.8 ± 16.7</td>
<td>0.839</td>
</tr>
<tr>
<td>95% CI</td>
<td>80.8, 99.4</td>
<td>82.7, 96.9</td>
<td></td>
</tr>
</tbody>
</table>

Reference ranges for our testing laboratory: cholesterol, total: 125–200 mg/dL; HDL cholesterol, ≥40 mg/dL; triglycerides, <150 mg/dL; hsCRP levels, 3.1–10.0 higher relative cardiac risk; HbA1c, <5.7%, no diabetes; 5.7%–6.4%, prediabetes or well-controlled; ≥6.5% diabetes.

* Median (min–max) for non-normal distribution.
† Mean ± standard deviation for normal distribution.
‡ Mann-Whitney rank sum test.
Higher in the diabetic group (169.0 mg/dL compared to 86.0 mg/dL, P = 0.004, Mann-Whitney rank sum test). Systolic and diastolic blood pressure ranges were not significantly different between diabetics and controls (median value 151.0 mm Hg versus 133.0 mm Hg for systolic and 90.1 ± 18.7 mm Hg versus 89.8 ± 17.4 mm Hg for diastolic, P = 0.206 and P = 0.839, respectively).

There were no significant differences in dry eye parameters between the diabetic group and controls (Table 3). With the exception of tear break-up time, all testing parameters were within normal values for a non-dry eye subject. Tear film break-up time was slightly lower in the control group, although not significant (median value of 5.5 seconds in diabetes compared to 4.8 seconds in the control, P = 0.765, Mann-Whitney rank sum test). Schirmer’s scores averaged 19.1 ± 8.2 mm for the diabetic group and 17.8 ± 7.9 mm for controls (P = 0.126, t-test). However, high density lipoproteins were significantly higher in the diabetic group (median value 44.0 mg/dL compared to 55.0 mg/dL, P = 0.040, Mann-Whitney rank sum test). Similarly, there was no difference in total cholesterol (177.8 ± 51.5 mg/dL versus 200.5 ± 34.4 mg/dL, P = 0.189, t-test). However, high density lipoproteins were significantly higher in the control group (median value 3.6 compared to 5.8 in diabetics and controls, respectively, P = 0.808, Mann-Whitney rank sum test).

Schirmer’s score, mm† 20.1
95% CI 16.2
NaFl staining* 0.5
OSDI score* 8.8
95% CI 14.4

g/dL, P = 0.024, Fig. 2C, Mann-Whitney rank sum test). There was also a significant reduction in the density of basal corneal epithelial cells from 1039.3 ± 19.4 cells/μm² in controls to 981.5 ± 18.0 cells/μm² in the diabetic group (P = 0.04, Fig. 2D, t-test). The mean concentration of IGFBP-3 in diabetic tears was 26.1 ±

**TABLE 4. Sex Differences in Dry Eye Parameters**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Male</th>
<th>Female</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 2 DM</td>
<td>5.7</td>
<td>4.9</td>
<td>0.213</td>
</tr>
<tr>
<td>(range)</td>
<td>(3.5–30.0)</td>
<td>(3.1–17.7)</td>
<td></td>
</tr>
<tr>
<td>Schirmer’s score, mm†</td>
<td>22.2 ± 7.4</td>
<td>17.5 ± 8.5</td>
<td>0.274</td>
</tr>
<tr>
<td>95% CI</td>
<td>14.4 ± 28.0</td>
<td>12.1 ± 22.9</td>
<td></td>
</tr>
<tr>
<td>NaFl staining*</td>
<td>(0–4.0)</td>
<td>(0–9.0)</td>
<td>1.000</td>
</tr>
<tr>
<td>(range)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OSDI score*</td>
<td>3.3</td>
<td>13.1</td>
<td>0.240</td>
</tr>
<tr>
<td>(range)</td>
<td>(0–56.3)</td>
<td>(0–39.6)</td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>5.2</td>
<td>4.5</td>
<td>0.789</td>
</tr>
<tr>
<td>(range)</td>
<td>(3.1–30.0)</td>
<td>(1.9–22.0)</td>
<td></td>
</tr>
<tr>
<td>Schirmer’s score, mm†</td>
<td>18.8 ± 6.8</td>
<td>16.5 ± 8.3</td>
<td>0.499</td>
</tr>
<tr>
<td>95% CI</td>
<td>13.6 ± 24.0</td>
<td>11.5 ± 21.5</td>
<td></td>
</tr>
<tr>
<td>NaFl staining*</td>
<td>(0–1.5)</td>
<td>(0–7.0)</td>
<td>0.026‡</td>
</tr>
<tr>
<td>(range)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OSDI score*</td>
<td>2.1</td>
<td>8.3</td>
<td>0.279</td>
</tr>
<tr>
<td>(range)</td>
<td>(0–64.5)</td>
<td>(0–41.7)</td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>5.7</td>
<td>4.6</td>
<td>0.189</td>
</tr>
<tr>
<td>(range)</td>
<td>(3.1–30.0)</td>
<td>(1.9–22.0)</td>
<td></td>
</tr>
<tr>
<td>Schirmer’s score, mm†</td>
<td>20.1 ± 7.0</td>
<td>17.0 ± 8.3</td>
<td>0.224</td>
</tr>
<tr>
<td>95% CI</td>
<td>16.2 ± 24.0</td>
<td>13.6 ± 20.4</td>
<td></td>
</tr>
<tr>
<td>NaFl staining*</td>
<td>(0–4.0)</td>
<td>(0–9.0)</td>
<td>0.051</td>
</tr>
<tr>
<td>(range)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OSDI score*</td>
<td>2.1</td>
<td>10.4</td>
<td>0.109</td>
</tr>
<tr>
<td>(range)</td>
<td>(0–56.3)</td>
<td>(0–64.5)</td>
<td></td>
</tr>
</tbody>
</table>

* Median (min–max) for non-normal distribution.
† Mean ± standard deviation for normal distribution.
‡ Student’s t-test.
7.2 μg/mL (Fig. 3A). This was significantly lower in the control group (7.5 ± 1.6 μg/mL, P < 0.05, t-test). HbA1c was not correlated with IGFBP-3 (R = 0.318, P = 0.062, power = 0.463, Fig. 3B). As expected, there was a strong correlation between nerve fiber length and nerve fiber branching, with shorter nerves having fewer branches (R = 0.767, P < 0.001, power = 1.000, Fig. 4A). Comparison of tear IGFBP-3 levels against nerve morphologic parameters showed strong correlations between nerve fiber length and IGFBP-3 (R = 0.522, P = 0.001, power = 0.906, Fig. 4B) and nerve branch density and IGFBP-3 (R = 0.481, P = 0.003, power = 0.842, Fig. 4C). Nerve fiber length was moderately correlated with HbA1c (R = 0.469, P = 0.004, power = 0.821, Fig. 5A), whereas nerve branch density was only weakly correlated with HbA1c (R = 0.394, P = 0.019, power 0.655, Fig. 5B).

DISCUSSION

This study showed, for the first time, a direct relationship between tear levels of IGFBP-3 and corneal nerve loss in patients with type 2 diabetes mellitus. We have previously shown that tears levels of IGFBP-3 are elevated in patients with diabetes.30 In that pilot study, we reported that the tear concentration of IGFBP-3 is approximately 3-fold higher in diabetics compared to nondiabetic controls. Limitations to that
study included a small sample size, a mixed population of type 1 and type 2 diabetic participants, and the absence of any dry eye testing that may account for the differences in tear concentration of IGFBP-3. Clinical signs of dry eye, such as reduced tear production, have been reported in diabetes. Thus, in this study we extended our prior results to exclude dry eye as the underlying cause for elevated IGFBP-3 levels. While the scores on the Ocular Surface Disease Index trended toward being slightly higher in the diabetic group compared to controls, reduced TFBUT measurements were borderline for both groups, suggesting mild dry eye may be present in a few patients in both the diabetics and controls. Importantly, there were no significant differences in any of the other dry eye parameters tested. The absence of retinopathy in the diabetic cohort presented here also suggests that these are somewhat well-controlled diabetics and may account the lack of significant dry eye findings.

Consistent with other laboratories, using in vivo confocal microscopy we demonstrated a reduction in nerve fiber length and nerve fiber branching in subjects with diabetes. We also found a significant reduction in the density of basal corneal epithelial cells. This finding is in agreement with work done by our laboratory reporting a decrease in the density of basal corneal epithelial cells in a streptozotocin mouse model of type 1 diabetes mellitus. In that study, we used three-dimensional corneal nerve modeling and found a significant decrease in nerve fiber length in the subbasal nerve plexus. While corneal sensitivity was not tested using our animal model, we did not detect any differences in the length of the terminal epithelial nerves. The terminal epithelial nerves are small nerve fibers that branch from the subbasal nerve plexus and course toward the corneal epithelial surface. Based upon those findings, we hypothesized that a robust amount of nerve fiber damage in the subbasal nerve plexus was required before corneal sensitivity was affected. That hypothesis was consistent with data from other studies that failed to show correlations between loss in corneal sensitivity and the reduction in nerve fiber length in the subbasal nerve plexus and is consistent with the findings presented here.

In the corneal epithelium, IGFBP-3 is upregulated in response to cellular stress. We have shown that IGFBP-3 increases in response to hyperglycemia. In proximal tubular epithelial cells, oxidative stress from hyperglycemic culture upregulates IGFBP-3 and potentiates apoptotic cell death. Similarly, increased levels of IGFBP-3 have been associated with apoptotic cell death in human mesangial cells following stress induced by the loss of growth factors during serum withdrawal.

We hypothesize that the increased secretory levels of IGFBP-3 may promote apoptosis or necrosis of corneal sensory nerves. In addition to direct effects by IGFBP-3 on corneal sensory nerves, IGFBP-3 is the principal binding protein for IGF-1, which is known to have potent neuroprotective effects.
actions. Sequestration of IGF-1 by IGFBP-3 may increase susceptibility of neuronal cell loss in the presence of hyperglycemia, inflammation, and oxidative stress, all known mediators of diabetic complications. IGF-1 has also been shown to be present in human tear fluid; however, IGF-1 levels are independent of the changes in IGFBP-3 in diabetic values. Thus, the shift in the IGF-1:IGFBP-3 ratio in diabetes may account for the reduction in corneal nerve fiber length and corneal nerve fiber branching through IGF-1 dependent and independent mechanisms. This contrasts with the effects of IGFBP-3 on corneal epithelial cells, where treatment with IGFBP-3 abrogates cell proliferation through IGF-1 inhibition. This perturbation in the proliferative status of basal corneal epithelial cells is a likely contributor to the alteration in basal corneal epithelial cell density reported here. It is important to note, however, that ELISAs were used to measure tear concentration of IGFBP-3. Thus, from the data presented, we cannot conclude whether the measurement of IGFBP-3 represents the whole, intact protein as opposed to cleavage fragments. IGFBP-3 is highly subject to proteolytic cleavage and cleavage will likely impact function. Further studies are necessary to investigate the state of IGFBP-3 in human tear fluid.

The relationship between HbA1c and loss of the subbasal nerve plexus is not well-defined. Confocal microscopic analysis of the increased tortuosity of the subbasal nerve plexus in diabetes is not associated with increasing levels of HbA1c. However, in healthy subjects HbA1c levels were inversely correlated with length of the subbasal nerve plexus. Likewise, studies have shown that in diabetic subjects, an improvement in HbA1c either from well-controlled medical therapy or simultaneous pancreas and kidney transplantation, there is a corresponding improvement in the subbasal nerve plexus from corneal nerve fiber regeneration. The present data show a weak to modest correlation between HbA1c and nerve fiber branch density and nerve fiber length. Furthermore, HbA1c failed to show any relationship with tear concentration of IGFBP-3. This suggests that while IGFBP-3 may be an indicator of ocular damage in diabetes, it is not directly related to blood sugar control. This is not altogether unsurprising since unlike type 1 diabetes mellitus, where tight glycemic control prevents long-term nerve damage, other factors than hyperglycemia alone contribute to diabetic complications, including ocular complications, in patients with type 2 disease.

As discussed above, IGFBP-3 levels were not affected by the objective dry eye parameters studied. While mild dry eye was suspect in both groups based on the shortened tear film break-up time, the difference between groups was not significant. Moreover, the trend toward an increase in the OSDI index score was higher in the diabetic group compared to the control. This too was not significant. Not surprisingly, analysis of the differences between sexes for dry eye parameters suggested potential mild dry eye among females. This sex effect was not reflected in differences in the nerve fiber layer of nerve fiber branching between groups and suggests that dry eye was not the driving factor for reduced nerve fiber length and nerve fiber branching between diabetics and controls in this study. Assessment of the subbasal nerve plexus in dry eye has shown significant alterations in both evaporative and aqueous deficient dry eye. This includes decreases in both the nerve fiber length and branch density. Importantly, the severity of the dry eye is known to correlate with the extent of the structural changes in the subbasal nerve plexus. Most prior studies have not compensated for the potential effects of diabetes-induced dry eye on the subbasal nerve plexus and this may account, in part, for the large variation in normative values reported in diabetic in vivo confocal microscopy studies.

Another difference between the current and prior studies is that volunteers in the current study were also matched for smoking status and obesity, conditions that have deleterious effects on the body through the increase of oxidative stress and inflammation.

In conclusion, the results presented here confirm our prior work demonstrating that the concentration of IGFBP-3 in human tear fluid is increased approximately 3-fold in diabetes. A limitation to this work is that we did not measure total protein, but reported levels of IGFBP-3 based upon the measured concentration. While total tear protein may be altered in diabetes, the marked increase in the concentration of IGFBP-3 reported in this study was significantly correlated with nerve fiber loss and a reduction in nerve fiber branching in the corneal subbasal nerve plexus. Taken together, these data suggest that tear concentration of IGFBP-3 may be an indicator for early diabetic corneal nerve damage. Further studies are underway to determine the exact function of IGFBP-3 in human corneal epithelium and the corresponding effects on trigeminal sensory nerves in the cornea as well; and to evaluate tear IGFBP-3 in diabetic patients that are stratified by severity of disease.

Acknowledgments
Supported by National Institutes of Health/National Eye Institutes Grants R21 EY024433 (DMR); R01 EY024546 (DMR); National Institutes of Health Core Grant P30 EY020799; and an unrestricted grant from Research to Prevent Blindness (New York, NY, USA).

Disclosure: W.L. Stuard, None; R. Titone, None; D.M. Robertson, None

References


